These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 34779643)

  • 21. Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies.
    Labriola MK; Atiq S; Hirshman N; Bitting RL
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):301-309. PubMed ID: 33168966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate cancer and PARP inhibitors: progress and challenges.
    Teyssonneau D; Margot H; Cabart M; Anonnay M; Sargos P; Vuong NS; Soubeyran I; Sevenet N; Roubaud G
    J Hematol Oncol; 2021 Mar; 14(1):51. PubMed ID: 33781305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data.
    Sigorski D; Iżycka-Świeszewska E; Bodnar L
    Target Oncol; 2020 Dec; 15(6):709-722. PubMed ID: 33044685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olaparib Targets Some Advanced Prostate Cancers.
    Cancer Discov; 2016 Jan; 6(1):OF1. PubMed ID: 26658963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Combination therapy with poly(adenosine diphosphate-ribose) polymerase (PARPi) and androgen receptor signaling pathway (ARPi) inhibitors for metastatic castration-resistant prostate cancer].
    Grimm MO; Foller S; Leucht K
    Urologie; 2023 Dec; 62(12):1269-1280. PubMed ID: 37978072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?
    Kwon DH; Booth CM; Prasad V
    Eur Urol; 2021 Jun; 79(6):710-712. PubMed ID: 33722420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
    Moore KN; Monk BJ
    Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing olaparib efficacy in U.S. Veterans with metastatic prostate cancer utilizing a time-indifferent g-rate method ideal for real-world analyses.
    Leuva H; Zhou M; Jamaleddine N; Meseha M; Faiena I; Anna Park YH; McWilliams G; Luhrs C; Maxwell KN; Von Hoff D; Bates SE; Fojo T
    EBioMedicine; 2024 Sep; 107():105288. PubMed ID: 39180789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer.
    Rescigno P; Chandler R; de Bono J
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):339-343. PubMed ID: 29979319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Poly-ADP ribose polymerase inhibitor and androgen receptor signaling inhibitor for all comers for first-line treatment of metastatic castration-resistant prostate cancer: is gene sequencing out?
    Higano CS; Cheng HH
    Curr Opin Urol; 2023 Sep; 33(5):396-403. PubMed ID: 37497748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation].
    Saillant A; Flippot R
    Bull Cancer; 2021 Feb; 108(2):140-142. PubMed ID: 33546874
    [No Abstract]   [Full Text] [Related]  

  • 32. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
    Unlu S; Kim JW
    Curr Oncol Rep; 2022 Nov; 24(11):1619-1631. PubMed ID: 35931885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
    Kim JW; McKay RR; Radke MR; Zhao S; Taplin ME; Davis NB; Monk P; Appleman LJ; Lara PN; Vaishampayan UN; Zhang J; Paul AK; Bubley G; Van Allen EM; Unlu S; Huang Y; Loda M; Shapiro GI; Glazer PM; LoRusso PM; Ivy SP; Shyr Y; Swisher EM; Petrylak DP
    J Clin Oncol; 2023 Feb; 41(4):871-880. PubMed ID: 36256912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
    Karzai F; VanderWeele D; Madan RA; Owens H; Cordes LM; Hankin A; Couvillon A; Nichols E; Bilusic M; Beshiri ML; Kelly K; Krishnasamy V; Lee S; Lee MJ; Yuno A; Trepel JB; Merino MJ; Dittamore R; Marté J; Donahue RN; Schlom J; Killian KJ; Meltzer PS; Steinberg SM; Gulley JL; Lee JM; Dahut WL
    J Immunother Cancer; 2018 Dec; 6(1):141. PubMed ID: 30514390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
    Dhawan M; Ryan CJ; Ashworth A
    Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overview of Olaparib as a treatment option for metastatic castration-resistant prostate cancer.
    Mourmouris P; Papatsoris A; Dellis A; Mitsogiannis I; Chakra MA; Moussa M
    Expert Opin Pharmacother; 2021 Oct; 22(15):1955-1959. PubMed ID: 34252319
    [No Abstract]   [Full Text] [Related]  

  • 37. PARP inhibitors in metastatic prostate cancer.
    Taylor AK; Kosoff D; Emamekhoo H; Lang JM; Kyriakopoulos CE
    Front Oncol; 2023; 13():1159557. PubMed ID: 37168382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New treatment approaches for and ongoing trials in metastatic hormone-sensitive prostate cancer].
    Isgandarov A; Darr C; Posdzich P; Hermann K; Hadaschik BA; Grünwald V
    Urologie; 2023 Apr; 62(4):369-375. PubMed ID: 36823372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
    Fujimoto N; Harada K; Shiota M; Tomisaki I; Minato A; Nagata Y; Kimuro R; Harada M; Fujisawa M
    Anticancer Res; 2021 Oct; 41(10):4687-4695. PubMed ID: 34593416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PARP inhibitors in castration-resistant prostate cancer.
    Tripathi A; Balakrishna P; Agarwal N
    Cancer Treat Res Commun; 2020; 24():100199. PubMed ID: 32745972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.